|Bid||60.13 x 3100|
|Ask||61.00 x 1100|
|Day's Range||60.07 - 61.22|
|52 Week Range||45.76 - 68.34|
|Beta (5Y Monthly)||0.68|
|PE Ratio (TTM)||N/A|
|Earnings Date||Nov 05, 2020|
|Forward Dividend & Yield||1.80 (2.99%)|
|Ex-Dividend Date||Oct 01, 2020|
|1y Target Est||73.69|
This alone makes it worthwhile for long-term investors to consider pharma stocks. Two that I think are worth buying right now are Bristol Myers Squibb (NYSE: BMY) and Alexion Pharmaceuticals (NASDAQ: ALXN). Both drugmakers are trading at attractive valuations: Bristol Myers' forward price-to-earnings (P/E) ratio is 8, while its price-to-earnings growth (PEG) is 0.81.
The healthcare is expected to witness substantial earnings growth of 5.1% in the third quarter, representing the second strongest sector this earnings season.
Bristol Myers stock has slipped this year. But acquiring Celgene has bolstered the pharmaceutical company's sales, and the pending acquisition of MyoKardia might also. So is BMY stock a buy?